Potential use of autologous stem/progenitor cells for urological tissue engineering and cell therapy
1. Introduction
Adult stem cells are defined as clonogenic, self-renewing progenitor cells that reside in adult tissues and can generate one or more specialized types of cells required for the function of that tissue. The majority of adult tissues contain their own stem/ progenitor cells that are capable of maintaining, generating, and replacing terminally differentiated cells within the tissue in response to physiologic cell turnover or tissue damage resulting from injury. Stem cell populations in the bone marrow were the first adult stem cell populations to be described, but in recent years adult stem populations have been demonstrated in the brain,[1, 2] skin, [3] and muscle [4], hair follicle and the gastrointestinal tract. Adult stem cells, especially hematopoietic stem cells, are the best understood cell type in stem cell biology [5], yet they remain an area of intense study, as their potential for therapy may be applicable to a myriad of degenerative disorders. These cells are a particularly attractive option for cell therapy and tissue engineering applications because they can be used in autologous therapies, thus avoiding any complications associated with immune rejection.
Research into adult stem cells has progressed slowly in the past, mainly because true stem cells are present in extremely low numbers in adult tissue[6-8], and because adult non-mesenchymal stem cells have been challenging to isolate, expand and maintain in culture. Some cells, such as those of the liver, pancreas and nerve, have very low proliferative capacity in vitro, and the functionality of some cell types is reduced after the cells are cultivated. These issues have limited the use of adult stem cells in tissue engineering and cell therapy research. However, the discovery of native targeted progenitor cells has allowed some of these limitations to be overcome. Native targeted progenitor cells are tissue specific unipotent cells derived from most organs. These cells are already programmed to become a specific cell type, and as with adult stem cells, native progenitor cells can be obtained from the specific organ to be regenerated, expanded, and used in the same patient without rejection, in an autologous manner [9-26]. By studying the niche in which the progenitor cells reside, as well as by exploring conditions that promote the differentiation of these cells, it has been possible to overcome some of the problems facing cell expansion in vitro. Major advances in cell culture techniques have been made within the past decade, and these techniques make the use of autologous cells possible for clinical application. In this chapter, we will focus on the use of autologous cells for regeneration and/or repair of the urinary tract.
2. Stem / progenitor cells derived from the genitourinary tract
Bladder
Adult human stem/progenitor cells from urinary tract system have been recently described and characterized [6,27]. It has been shown experimentally that the bladder neck and trigone area have a higher density of urothelial progenitor cells [28], and these cells are localized in the basal region [29]. In the past, it was possible to grow urothelial cells in the laboratory setting, but only with limited success. However, several protocols have been developed over the last two decades that have improved urothelial growth and expansion by enhancing culture conditions to support proliferation and differentiation of urothelial progenitor cells [17, 30-32]. It is now possible to expand a urothelial strain from a single surgical specimen that initially covers a surface area of 1 cm2 to one covering a surface area of 4202 m2 (the equivalent area of one football field) within 8 weeks[17]. Now, normal human bladder epithelial and muscle cells can be efficiently harvested from surgical material, extensively expanded in culture, and their differentiation characteristics, growth requirements, and other biologic properties can be studied [17, 19, 20, 31-40]. In addition, human urothelial and muscle cells can attach and form sheets of cells when seeded onto polymer scaffolds. The cell-polymer scaffold can then be implanted for repairing urological tissue defects. Histological analysis indicates that, within the cell-polymer construct, viable cells are able to self assemble back into their respective tissue types, and they retain their native phenotype [11].
To determine whether these engineered tissues could be implanted in continuity with the urinary tract, large animal models of bladder augmentation were used [22]. Partial cystectomies were performed in dogs and the animals were divided into 2 experimental groups. In one group, the bladder was augmented with a non-seeded bladder-derived collagen matrix, and in the second group, the bladder was augmented with a cell-seeded construct. The bladders augmented with seeded matrices demonstrated a 100% increase in capacity compared with bladders augmented with cell-free matrices, which only generated a 30% increase in capacity.
It has been known for a number of years that the bladder is able to regenerate generously over cell-free scaffolds, because urothelium has a high reparative capacity [41]. However, bladder muscle tissue is less likely to regenerate in the same fashion as urothelium, which leads to contracture or resorption of the graft. In addition, the inflammatory response toward the materials used to form the graft matrix may contribute to the resorption of cell-free grafts as well. The dog study demonstrated a major difference between matrices used with autologous cells (tissue-engineered matrices) and those used without cells [22]. The matrices seeded with cells prior to use in bladder augmentation retained most of their implanted diameter, as opposed to the matrices implanted without cells, in which graft contraction and shrinkage occurred. As in previous studies, the histomorphology demonstrated a lack of muscle cells and a more aggressive inflammatory reaction in the unseeded matrices.
The results of initial studies showed that the creation of tissue engineered bladders using autologous urothelial and smooth muscle cells could be achieved; however, it could not be determined whether the improvement in functional parameters noted was due to the implanted segment or to the remaining native bladder tissue. To better address the functional parameters of tissue-engineered bladders, additional animal model of subtotal cystectomy with subsequent replacement with a tissue-engineered organ was created[25]. In this model cystectomy-only and non-seeded controls maintained average capacities of 22% and 46% of preoperative values, respectively. An average bladder capacity of 95% of the original precystectomy volume was achieved with the cell-seeded tissue engineered bladder replacements. These findings were confirmed radiographically. The subtotal cystectomy reservoirs that were not reconstructed and the reservoirs reconstructed with unseeded grafts showed a marked decrease in bladder compliance (10% and 42% total compliance, respectively). In contrast, the compliance of the tissue-engineered bladders showed almost no difference from preoperative values (106%). Histologically, the non-seeded scaffolds resulted in a structure composed of normal urothelial cells with a thickened fibrotic submucosa and a thin layer of muscle fibers. The retrieved tissue-engineered bladders showed a normal cellular organization, consisting of a trilayer of urothelium, submucosa, and muscle. Immunocytochemical analyses confirmed the muscle and urothelial phenotypes, and indicated the presence of neural structures [25]. These studies, performed with polyglocolic acid based-scaffolds, have been repeated by other investigators, showing similar results in large numbers of animals long-term [42, 43]. Subsequent studies indicated that biodegradable scaffolds seeded with cells can be used without concerns for local or systemic toxicity [44].
Bladder tissue engineered using autologous cells has been used clinically. A small clinical study was conducted starting in 1998. Seven patients were treated using a collagen scaffold seeded with cells taken from biopsies of their own bladders, either with or without omental coverage, or a combined PGA-collagen scaffold seeded with cells and omental coverage. The patients reconstructed with the engineered bladder tissue created with the PGA-collagen cell-seeded scaffolds with omental coverage showed increased compliance, decreased end-filling pressures, increased capacities and longer dry periods over time [45]. It is clear from this small study that the engineered bladders continued their improvement with time, suggesting continued development in vivo. Although the experience is promising, it is just a start and the technology is not yet ready for wide dissemination, as further experimental and clinical studies are required.
Kidney
Kidney has long been considered an organ that is incapable of true regeneration. Furthermore, the question of whether or not the kidney contains adult stem cells remains controversial. However, increasing evidence of a regenerative response in the kidney has been observed following the injury resulting from both toxic and ischemic insults. These observations include evidence of renal progenitors of specific cell types involved in the formation of new renal tubular cells and the recovery of renal function recovery after ischemic injury. The presence of injured or dead cells following ischemia causes denudation of the tubular basement membrane, and sloughed cells and cellular debris fills tubular lumens. The kidney responds to the ischemic injury with a prompt regenerative response, resulting in regenerating tubules and improving kidney function. Although they remain elusive, the cells participating in renal regeneration are likely from pools of both exogenous and endogenous stem cells. The exogenous stem cells are probably largely derived from bone marrow, and may be both hematopoietic and mesenchymal stem cells. In some studies, these cells appear to home to damaged sites in the injured kidney and form tubular epithelial cells following acute renal injury [46-49]. These MSC might also produce growth factors such as IGF-1 to promote renal repair [50]. The endogenous stem cells are resident kidney stem cells found in the renal tubules and the papilla[51, 52]. They are inactivated under physiological conditions. These stem cells posses the capacity to give rise renal tubule cells following injury repair [53, 54]. A recent study showed that repopulation of damaged renal tubules occurs primarily from proliferation of tubular epithelial cells and resident renal-specific stem cells, with some contribution of paracrine factors from bone marrow-derived mesenchymal stem cells [55-56].
Testis
Primordial germ cells (PGC) are the embryonic progenitor cells of the gametes (spermatogonial stem cells and ova).
For regenerative medicine purposes, PGC are not ideal, because they are derived from embryos and there are a number of controversial ethical issues surrounding the manipulation of human embryos. However, there has been much interest in isolating and describing spermatogonial stem cells (SSC) in recent years. The presence of SSC, which are derived from PGC in the testis, was originally inferred from the presence of ongoing spermatogenesis in the adult male. Recently, the cells believed to be the actual SSC were isolated from the adult testis of both mice and humans through selection of the markers STRA-8, GPR125, CD49fm, CD133 and others[58, 59] [60]. Interestingly, when SSC from both mice and humans are cultured in specified media containing growth factors known to be required for maintenance of pluripotency of other types of stem cells, such as leukemia inhibitory factor (LIF) and glial cell line-derived neurotrophic factor (GDNF), they appear to convert to an embryonic stem (ES) cell like state.[60] These converted cells have been termed adult germline stem cells (aGSC) and they can differentiate into a number somatic cell types encompassing all three embryonic germ layers when they are exposed to the same conditions used to differentiate ES cells. They also form teratomas when implanted
Urine
We recently demonstrated that it is possible to isolate and expand stem/progenitor cells from human urine[6]. Approximately, 0.2% of cells collected from urine express markers characteristic of mesenchymal stem cells (MSC), can expand extensively in culture, and can differentiate towards multiple bladder cell lineages as identified by the expression of urothelial, smooth muscle, endothelial and interstitial cell markers. We initially referred to these cells as urine progenitor cells. However, our more recent experiments indicated that urine-derived cells can give rise to additional specialized types, including osteocytes, chondrocytes, and adipocytes. Furthermore, these cells have self-renewal capability consistent with stem cells. There is now sufficient evidence to provisionally designate them as urine-derived stem cells (USC).
Three types of cells exist in urine: differentiated, differentiating and progenitor cells. Most cells in urine are fully differentiated. They do not attach to tissue culture plates. About 0.1% of cells in urine are differentiating cells, which do attach to plates and display the morphology and protein markers of various bladder cell lineages. However, these cells do not expand further after subculture. About 0.2% of the cells in urine have a phenotype consistent with multipotent stem cells. USC are easily cultured, appear genetically stable after a number of passages, and maintain the ability to give rise to more differentiated progeny.
USC comprise an average of about 7 cells/100ml urine (from 5 to 10 cells/100 ml urine). We have shown that, a few days after being placed in a tissue culture well, a single cell forms a cluster of cells which appeared small, compact and uniform. A consistently high yield of cells was achieved from each of these clonal lines. The cells reached confluence in about two weeks when placed in a 3-cm diameter well at passage one. At passage 2, cells were plated in 10 cm culture dishes and a cell number of approximately one million was reached in 3.5 weeks. Finally, in six to seven weeks, the cultures expanded to approximately 100 million cells at passage four. These cells displayed normal exponential cell growth patterns, with a steady increase in cell numbers during a 10-day culture period. The average population doubling time was 31.3 hours in mixed media. These urine-derived cells also showed the ability to differentiate into various cell lineages as described below, and were capable of growing for at least 14 passages
Cells from human urine specimens could be consistently cultured long-term using a medium that we originally developed for culture of rat urothelium[61]. However, the phenotype of the cultured human urine-derived cells was not that of primary urothelial cells. The primary cultures from urine did not show expression of the cytokeratins (CK7, CK13, and CK19/20), which are characteristic of epithelial cells, nor did the cells express the urothelial-specific protein uroplakin. After growth in medium containing higher levels of epidermal growth factor (EGF), the cells were induced efficiently to express the cytokeratin proteins and uroplakin[6]. However, after growth in myogenic medium, the cultured cells expressed markers consistent with smooth muscle, including alpha-smooth muscle actin (α-SM actin), desmin, calponin, and myosin[6]. This led us to conclude that the urine-derived cells were progenitors (initially designated UPC) capable of giving rise to both urothelium and bladder smooth muscle. Furthermore, we found that the cells displayed a surface marker phenotype consistent with mesenchymal stem cells (MSC). Specifically, they expressed CD 44, CD73, CD90, CD105, and CD 146, and they were negative for both hematopoietic markers and endothelial markers including CD45, CD34, and CD31. We concluded that the urine-derived progenitors were at least bipotential for the major bladder cell types. This result was surprising, because it was generally believed that muscle and epithelial cells in bladder represent separate cell lineages derived from mesoderm and endoderm, respectively. We have recently observed that the urine-derived cells express markers typical of mesenchymal stem cells (MSC) and pericytes, and that they can differentiate to yield the characteristic cell lineages obtained from MSC, namely, osteocytes, adipocytes and chondrocytes [62].
In our recent study, USC clones could be obtained from 85% of urine sample tested. Fresh urine gave the highest rate of colony formation (67%) and urine stored at 4 C the lowest (30%). Urine from volunteers aged 13-40 gave the highest rate of clone recovery. Catheterization significantly enhanced the number of USC in urine compared to spontaneously voided urine, possibly because catheterization resulted in cells being scraped off the inner bladder wall. Collecting triple urine samples increased the rate of clone formation.
There are many potential advantages to using USC as a cell source for urological tissue engineering. First, cells can be easily harvested and grown in culture. USC do not require enzyme digestion or culture on a layer of feeder cells to support cell growth. Second, since invasive surgical biopsy procedures are not necessary to harvest cells from urine, patient morbidity and potential complications, such as urethral or bladder trauma and urinary tract infections, are avoided. As USC are autologous somatic cells, no ethical issues are involved in their use for tissue reconstruction, and no immune reaction to engineered implants should occur.
The quality of cells obtained from urine is similar to that of the biopsy-derived cells described above. When differentiated, USC express all proteins characteristic of the various bladder cell lineages. Karyotype analysis has demonstrated that these cells are genetically stable. Importantly, there is a major cost advantage to using USC – it costs about $50 to obtain cells from urine, versus about $5,000 to isolate cells from a biopsy procedure[6]. About 1.4 x10[9] urothelial and smooth muscle cells (SMC) are required for bladder tissue regeneration[63]. We estimate that 3-4 urine samples (about 40-45 USC/600 ml urine) expanded for 4-5 weeks would yield a sufficient quantity of low passage, healthy cells for clinical tissue engineering applications. This time frame is comparable to that required for expansion from a tissue biopsy (7-8 weeks)[64]. USC and the cells obtained through urological tissue biopsies come from the same urinary tract systems and have similar biological features. Therefore, collecting cells from urine could be an attractive alternative to the standard urological tissue biopsies currently used in cell therapy and tissue engineering.
3. Stem/progenitor cells derived from non-urological tissues
Despite the convenience of using differentiated cells in tissue engineering applications, these cells have several shortcomings. These cells have a limited ability to grow in culture and they tend to dedifferentiate
Mesenchymal stem cells
Mesenchymal stem cells (MSC), isolated from bone marrow, skeletal muscle, and adipose tissue, possess the capacity to differentiate into cells of connective tissue lineages, including muscle. Isolation and characterization of MSC, and control of their myogenic differentiation derived from both pre-clinical and clinical studies have attracted attention to their potential use in urological regenerative medicine and tissue engineering.
Currently, the most effectively characterized types of multipotent stem cells are from bone marrow. Bone marrow stem cells (BMSC) have been shown to differentiate into specialized cells, including hepatocytes[65-67], neural cells[68-71] and mainly mesodermal derivatives such as bone, cartilage, cardiac muscles, skeletal muscle, and fat. If BMSC are placed on a proper bio-degradable scaffold and implanted, they can act as anti-fibrotic, angiogenic, anti-apoptotic, and mitotic agents. Recently, BMSC were evaluated as an alternative cell type for use in replacement of bladder SMC when native bladder muscle tissue is unavailable. The potential of BMSC to differentiate into cells with bladder SMC characteristics was assessed in vitro[72] and in different animal models [73-78]. Kanematsu et al[75] showed that in vitro, both supernatants from cultured rat bladder cells (conditioned media) or media containing TGF-β and VEGF induced bone marrow cells to adopt a SMC phenotype. Recently, we have investigated the impacts of soluble growth factors, bladder extracellular matrix (ECM), and 3D dynamic culture on cell proliferation and differentiation of human BMSC into smooth muscle cells (SMC)[72]. Myogenic growth factors (PDGF-BB and TGF-β1) alone, or combined either with bladder ECM or dynamic cultures, induced BMSC to express smooth muscle specific genes and proteins. Either ECM or the dynamic culture alone promoted cell proliferation but did not induce myogenic differentiation of BMSC. A highly porous nanofibrous poly-L-lactic acid (PLLA) scaffold provided a 3D structure for maximizing the cell-matrix penetration, maintained myogenic differentiation of the induced BMSC, and promoted tissue remolding with rich capillary formation in vivo. This study demonstrates that myogenic-differentiated BMSC seeded on a nanofibrous PLLA scaffold can be used for cell-based tissue engineering for bladder cancer patients requiring cystoplasty.
In order to test this
Other MSC such as skeletal muscle-derived progenitor cells [79-88] [89-92] and adipose stem cells[80, 90, 91, 93-98] have been investigated as potential candidates for cell-based tissue engineering and injection therapy stress urinary incontinence (SUI), and these studies are further described in Section 5.
Induced pluripotent stem cells
iPS cells are a type of pluripotent stem cell that is artificially derived from a patient’s own somatic cells (a non-pluripotent cell) by inducing a "forced" expression of certain genes. iPS cells were first produced in 2006 from mouse cells and then in 2007 from human cells. iPS cells are typically derived by transfecting stem cell-associated genes into non-pluripotent cells, such as adult fibroblasts. Transfection is typically achieved through viral vectors, such as retroviruses. Transfected genes include the master transcriptional regulators Oct-3/4 (Pouf51) and Sox2, although it is suggested that other genes may enhance the efficiency of induction. After 3–4 weeks, small numbers of transfected cells begin to become morphologically and biochemically similar to pluripotent stem cells, and these cells are typically isolated through morphological selection or through a reporter gene and/or antibiotic selection. This has been cited as an important advancement in stem cell research, as it may allow researchers to obtain pluripotent stem cells, which are important in research and potentially have therapeutic uses in urology, without the controversial use of embryos.
iPS cells are believed to be similar to natural pluripotent stem cells, such as embryonic stem (ES) cells in many respects, including expression of certain stem cell genes and proteins, chromatin methylation patterns, doubling time, embryoid body formation, teratoma formation, viable chimera formation, potency and differentiability, but the full extent of their relation to natural pluripotent stem cells is still being assessed.
However, depending on the methods used, reprogramming of adult cells to obtain iPS cells may pose significant risks that currently limit the use of this technique in human therapy. For example, if viruses are used to genetically alter the cells, expression of oncogenes may potentially be triggered. In February 2008, a report published in the journal
Human Amniotic Fluid Stem Cells
Human amniotic fluid cells are commonly used clinically as a diagnostic tool for the prenatal diagnosis of fetal genetic anomalies. Recently, increasing evidence demonstrated that fetal-derived stem cells can be isolated from amniotic fluid. These cells represent a novel class of pluripotent stem cells with intermediate characteristics between embryonic and adult stem cells, as they are capable of giving rise to lineages representative of all three germ layers but do not form teratomas when implanted
4. Approaches for inducing myogenic differentiation of stem cells
When stem cells are used as a cell source for urological tissue engineering and regeneration, they can be used three ways: 1) stem cells can be induced to differentiate into the target cells/tissue–like cells
Current research tends to focus largely on the first strategy described above to allow control over the signals that the cells receive so that differentiation into the tissue type required progresses without problems. For this strategy, it is necessary to mimic the physiological conditions that guide stem cells to differentiate into the desired target cells before implantation. For example, several factors have been shown to enhance autologous adult stem cell differentiation into functional SMC, including:
Growth factors, such as vessel endothelial growth factor (VEGF), platelet-derived growth factor (PDGF-BB), transforming growth factor-β (TGF-β) and insulin-like growth factor (IGF)[104],
Components of the extracellular matrix (ECM). Cellular interactions with the ECM play an important role in cell adhesion, growth, migration, apoptosis and differentiation [105]. It consists of compounds such as collagen, laminin [106], and fibronectin. Collagen IV can promote embryonic stem cells to differentiate into stem cell antigen-1-positive (Sca-1[+]) progenitor cells and SMC[107]. However, ECM can promote adult cell proliferation or improve the yield of SMC derived from adult MSC, but ECM alone cannot induce adult MSC to differentiate into SMC[108, 109]. Additionally, culture on a three-dimensional ECM scaffold in a dynamic culture system can improve cell proliferation, maintain cell phenotypes and lead to a more homogenous distribution of cells on the scaffold [110,] [111] when compared to 2-D static culture.
The application of cyclic mechanical strain to cell cultures has been demonstrated to increase the expression of smooth muscle cell markers in stem cells[113]. Periodic stretching occurs
5. Autologous stem cells for endoscopic therapies
Another exciting area of clinical urologic investigation is the use of various autologous cells to treat vesicoureteral reflux (VUR) and SUI. An increasing number of clinical trials using tissue engineering approaches have been reported (Table 1). All of these clinical applications of urological tissue engineering are based on a series of successful animal experiments[115,] [116, 117].
Cell types | Require Tissue biopsy | Highly expandable | Potential applications | Clinical trail |
Skeleton muscle derived progenitor cells | Yes | Cell therapy for VRU and urinary incontinent, Bladder regeneration | Yes | |
Bone marrow stem cells | Yes | Depend on age | Tissue engineered bladder; Cell therapy for VRU; urinary incontinent | Yes |
Adipose stem cells | Yes | Tissue engineered bladder; | Yes | |
Urine progenitor cells | No | no depend on age | Tissue engineered urological organs | No |
Endoscopic therapy offers a simple method for definitive treatment in SUI and VUR. Two types of injectable substances have been investigated. First, natural and synthetic biomaterials that serve as bulking agents, such as silicone, fibrin, bioglass, polyvinyl alcohol foam, alginate gel, a small-intestinal submucosal suspension and Defulx have been used[118]. Currently, injectable therapy based on bulking agents is used for only about two-thirds of patients with SUI, with even lower cure rates. Potential problems of these injectable substances include decreasing volume of the injectable substance over time
Cell-based therapy is a promising alternative in urological procedures for VUR and USI. Autologous cells that can be used for this purpose include chondrocytes[115, 119], adipose-derived stem cells (ASC) [120-122], BMSC [121, 123], and skeletal muscle derived progenitor cells [85, 124-127]. In 1994, Atala et al proposed the use of injectable autologous chondrocytes to correct VUR via endoscopy [12, 128]. Using a minipig model, they noted that autologous chondrocytes injected around the ureter to stop reflux did not migrate and the cartilage bead produced by this technique maintained its volume with time. Reflux was corrected in all animals treated endoscopically with autologous chondrocytes. After these successful animal experiments, several clinical trials have begun[115, 119]. One study [129] was conducted in a total of 29 children (46 ureters) with grades II to IV reflux. Chondrocytes were harvested from a biopsy of each patient’s ear cartilage and were grown in culture for 6 weeks. Patients then returned to the clinic for transurethral injection of chondrocytes into the bladder trigone to correct reflux. Ultrasound was performed 1 month after this procedure and radionuclide cystography was done 3 months postoperatively to confirm reflux resolution. When reflux persisted, repeat treatment with stored chondrocytes was offered. In this study, a single chondrocyte injection corrected reflux in 26 of the 46 ureters (57%), while secondary injection was successful in 12 of 19 (63%). Overall, reflux was corrected in 38 of the 46 ureters (83%) and in 24 of the 29 patients (83%). There were no significant complications, and transurethral injection of autologous chondrocytes to correct VUR in children appears to be an effective and safe technique. The only limitation of this therapy is the high cost.
The use of myocyte- and stem cell-based injection therapy has also been tested in VUR cases. Primary VUR is a congenital anomaly of the ureter-vesical junction that creates a deficiency of the longitudinal muscle of the intravesical ureter. This leads to an inadequate valvular mechanism and allows urine to flow backward from the bladder to the kidney. Thus, myocyte-based therapies are attractive options for the recovery of this muscle defect at the ureteral orifice.
Autologous progenitor cell-based therapy has also made significant progress in treatment of SUI. This cell therapy could soon become a standard procedure. The objective of this therapy is to improve or cure the sphincter dysfunction via periurethral endoscopic injection. Currently, myoblasts obtained from skeletal muscle biopsies and adipose-derived cells are the most commonly used cells for therapy for SUI. Recently, autologous myoblasts and fibroblasts have been evaluated as a potential injectable therapy for SUI. One group[130-133] has studied a combination therapy consisting of autologous myoblasts injected into the rhabdosphincter and fibroblasts injected into the urethral submucosa. A year follow-up study of 123 women was performed from 2004 to 2005. A cure rate of about 79% with improvements in quality-of-life scores, rhabdosphincter contractility, and urethral closure pressures has been achieved. All patients were continent 1 year after receiving this therapy and maintained their good outcome at further follow-up visits. Ultrasound images before treatment clearly revealed poor periurethral integrity of the sphincteric mechanism; postinjection images revealed a completely normal-appearing urethra.
Rodriguez
6. Conclusions
Current advances in urological tissue engineering and stem cell-based therapy demonstrate that bladder and urethral tissues can be regenerated using autologous cells seeded onto biodegradable scaffolds. VUR and SUI can be corrected with injections of autologous stem cells contained in a hydrogel. However, many issues must be elucidated before these techniques can become widely used in the clinic. For example, the role of donor cells in tissue regeneration remains unclear, and it is not known whether the seeded stem cells proliferate and populate scaffold materials themselves, or if they stimulate to the activation, migration, proliferation, and differentiation of the local progenitor cells to complete the tissue regeneration. Additionally, an approach to promote angiogenesis and to facilitate innervation with a functional network of regenerated nerves will greatly improve tissue regeneration strategies to create a de novo urological organ. (6,015 words)
References
- 1.
Jiao J. Chen D. F. Induction of. neurogenesis in. nonconventional neurogenic. regions of. the adult. central nervous. system by. niche astrocyte-produced. signals 1221 EOF 1230 EOF 2008 - 2.
Taupin, P.: Therapeutic potential of adult neural stem cells. Recent Patents CNS Drug Discov, 1: 299,2006 - 3.
, 121:Jensen U. B. Yan X. Triel C. et al. distinct A. population of. clonogenic multipotent murine. follicular keratinocytes. residing in. the upper. isthmus 609 EOF 17 EOF 2008 - 4.
, 26: 2425,Crisan M. Casteilla L. Lehr L. et al. reservoir A. of brown. adipocyte progenitors. in human. skeletal muscle. 2008 - 5.
Supplement, 38:Ballas C. B. Zielske S. P. Gerson S. L. Adult bone. marrow stem. cells for. cell gene therapies. implications for. greater use. 20 EOF 8 EOF 2002 - 6.
, 180:Zhang Y. Mc Neill E. Tian H. et al. Urine derived. cells are. a. potential source. for urological. tissue reconstruction. 2226 EOF 2233 EOF 2008 - 7.
Mimeault M. Batra S. K. Recent progress. on tissue-resident. adult stem. cell biology. their therapeutic. implications 27 EOF 49 EOF 2008 - 8.
, 389:Hristov M. Zernecke A. Schober A. et al. Adult progenitor. cells in. vascular remodeling. during atherosclerosis. 837 EOF 844 EOF 2008 - 9.
, 148:Atala A. Vacanti J. P. Peters C. A. et al. Formation of. urothelial structures. in vivo. from dissociated. cells attached. to biodegradable. polymer scaffolds. in vitro. 658 EOF 62 EOF 1992 - 10.
, 150:Atala A. Cima L. G. Kim W. et al. Injectable alginate. seeded with. as chondrocytes a. potential treatment. for vesicoureteral. reflux 745 EOF 7 EOF 1993 - 11.
, 150:Atala A. Freeman M. R. Vacanti J. P. et al. Implantation in. vivo retrieval of. artificial structures. consisting of. rabbit human urothelium. human bladder. muscle 608 EOF 12 EOF 1993 - 12.
, 152:Atala A. Kim W. Paige K. T. et al. Endoscopic treatment. of vesicoureteral. reflux with. a. chondrocyte-alginate suspension. 641 EOF 3%3B EOF 1994 - 13.
153,Atala A. Schlussel R. N. Retik A. B. Renal cell. growth in. vivo after. attachment to. biodegradable polymer. scaffolds 1995 - 14.
, 162:Atala A. Guzman L. Retik A. B. novel A. inert collagen. matrix for. hypospadias repair. 1148 EOF 51 EOF 1999 - 15.
Atala, A.: Tissue engineering in the genitourinary system. In: . Edited by A. Atala and D. J. Mooney. Boston, MA: Birkhauser Press,149 1997 - 16.
Atala, A.: Autologous cell transplantation for urologic reconstruction. Journal of Urology, 159:2 EOF 3 EOF 1998 - 17.
, 152:Cilento B. G. Freeman M. R. Schneck F. X. et al. Phenotypic cytogenetic characterization. of human. bladder urothelia. expanded in. vitro 665 EOF 70 EOF 1994 - 18.
, 158:Yoo J. J. Atala A. novel A. gene delivery. system using. urothelial tissue. engineered neo-organs. 1066 EOF 70 EOF 1997 - 19.
, 33:Fauza D. O. Fishman S. J. Mehegan K. et al. Videofetoscopically assisted. fetal tissue. engineering skin. replacement 357 EOF 61 EOF 1998 - 20.
, 33:Fauza D. O. Fishman S. J. Mehegan K. et al. Videofetoscopically assisted. fetal tissue. engineering bladder. augmentation 7 EOF 12 EOF 1998 - 21.
Machluf, M., Atala, A.: Emerging concepts for tissue and organ transplantation. , 1: 31,1998 - 22.
51:Yoo J. J. Meng J. Oberpenning F. et al. Bladder augmentation. using allogenic. bladder submucosa. seeded with. cells 221 EOF 5 EOF 1998 - 23.
Urologic Clinics of North America, 26:Amiel G. E. Atala A. Current future modalities. for functional. renal replacement. 235 EOF 46%2C EOF 1999 - 24.
, 26:Kershen R. T. Atala A. New advances. in injectable. therapies for. the treatment. of incontinence. vesicoureteral reflux. 81 EOF 94%2C EOF 1999 - 25.
, 17: 149,Oberpenning F. Meng J. Yoo J. J. et al. De novo reconstitution. of a. functional mammalian. urinary bladder. by tissue. engineering.[see comment]. 1999 - 26.
, 162:Park H. J. Yoo J. J. Kershen R. T. et al. Reconstitution of. human corporal. smooth muscle. endothelial cells. in vivo. 1106 EOF 9 EOF 1999 - 27.
, 178:Oottamasathien S. Williams K. Franco O. E. et al. Urothelial inhibition. of transforming. growth factor-beta. in a. bladder tissue. recombination model. 1643 EOF 9 EOF 2007 - 28.
, 40:Nguyen M. M. Lieu D. K. de Graffenried L. A. et al. Urothelial progenitor. cells regional. differences in. the rat. bladder 157 EOF 165 EOF 2007 - 29.
A, 294:Kurzrock E. A. Lieu D. K. Degraffenried L. A. et al. Label-retaining cells. of the. bladder candidate. urothelial stem. cells F1415 EOF 21 EOF 2008 - 30.
, 158:Scriven S. D. Booth C. Thomas D. F. et al. Reconstitution of. human urothelium. from monolayer. cultures 1147 EOF 52 EOF 1997 - 31.
, 61:Liebert M. Hubbel A. Chung M. et al. Expression of. mal is. associated with. urothelial differentiation. in vitro. identification by. differential display. reverse-transcriptase polymerase. chain reaction. 177 EOF 85 EOF 1997 - 32.
, 462:Puthenveettil J. A. Burger M. S. Reznikoff C. A. Replicative senescence. in human. uroepithelial cells. 83 EOF 91 EOF 1999 - 33.
9:Liebert M. Wedemeyer G. Abruzzo L. V. et al. Stimulated urothelial. cells produce. cytokines express an. activated cell. surface antigenic. phenotype 124 EOF 30 EOF 1991 - 34.
, 45: 786,Tobin M. S. Freeman M. R. Atala A. Maturational response. of normal. human urothelial. cells in. culture is. dependent on. extracellular matrix. serum additives. 1994 - 35.
, 75 Suppl 1:Harriss D. R. Smooth muscle. cell culture. a. new approach. to the. study of. human detrusor. physiology pathophysiology 18 EOF 26 EOF 1995 - 36.
, 99:Freeman M. R. Yoo J. J. Raab G. et al. Heparin-binding E. G. F-like growth. factor is. an autocrine. growth factor. for human. urothelial cells. is synthesized. by epithelial. smooth muscle. cells in. the human. bladder 1028 EOF 36 EOF 1997 - 37.
, 132: 279,Solomon L. Z. Jennings A. M. Sharpe P. et al. Effects of. short-chain fatty. acids on. primary urothelial. cells in. culture implications. for intravesical. use in. enterocystoplasties.[see comment]. 1998 - 38.
, 153:Lobban E. D. Smith B. A. Hall G. D. et al. Uroplakin gene. expression by. normal neoplastic human. urothelium 1957 EOF 67 EOF 1998 - 39.
, 35:Nguyen H. T. Park J. M. Peters C. A. et al. Cell-specific activation. of-E the. H. B. G. F. Erb B. genes by. stretch in. primary human. bladder cells. 371 EOF 375 EOF 1999 - 40.
, 162:Rackley R. R. Bandyopadhyay S. K. Fazeli-Matin S. et al. Immunoregulatory potential. of urothelium. characterization of. N. F-kappa B. signal transduction. 1812 EOF 6 EOF 1999 - 41.
, 145:de Boer W. I. Schuller A. G. Vermey M. et al. Expression of. growth factors. receptors during. specific phases. in regenerating. urothelium after. acute injury. in vivo. 1199 EOF 207 EOF 1994 - 42.
, 3:Jayo M. J. Jain D. Ludlow J. W. et al. Long-term durability. tissue regeneration. neo-organ growth. during skeletal. maturation with. a. neo-bladder augmentation. construct 671 EOF 682 EOF 2008 - 43.
, 180: 392,Jayo M. J. Jain D. Wagner B. J. et al. Early cellular. stromal responses. in regeneration. versus repair. of a. mammalian bladder. using autologous. cell biodegradable scaffold. technologies.[see comment]. 2008 - 44.
, 179:Kwon T. G. Yoo J. J. Atala A. Local systemic effects. of a. tissue engineered. neobladder in. a. canine cystoplasty. model 2035 EOF 2041 EOF 2008 - 45.
, 367: 1241,Atala A. Bauer S. B. Soker S. et al. Tissue-engineered autologous. bladders for. patients needing. cystoplasty.[see comment]. 2006 - 46.
Lin, F.: Renal repair: role of bone marrow stem cells. , 23:851 EOF 861 EOF 2008 - 47.
Lin, F.: Stem cells in kidney regeneration following acute renal injury. , 59:74R EOF 8R EOF 2006 - 48.
Krause, D., Cantley, L. G .: Bone marrow plasticity revisited: protection or differentiation in the kidney tubule? 115: 1705,2005 - 49.
, 112:Kale S. Karihaloo A. Clark P. R. et al. Bone marrow. stem cells. contribute to. repair of. the ischemically. injured renal. tubule 42 EOF 9 EOF 2003 - 50.
, 18:Imberti B. Morigi M. Tomasoni S. et al. Insulin-like growth. factor sustains stem. cell mediated. renal repair. 2921 EOF 8 EOF 2007 - 51.
J. A., Maarouf, O., Cheema, F. H. et al.: The renal papilla is a niche for adult kidney stem cells., 114:Oliver J. A. Maarouf O. Cheema F. H. et al. The renal. papilla is. a. niche for. adult kidney. stem cells. 795 EOF 804 EOF 2004 - 52.
, 17:Maeshima A. Sakurai H. Nigam S. K. Adult kidney. tubular cell. population showing. phenotypic plasticity. tubulogenic capacity. integration capability. into developing. kidney 188 EOF 98 EOF 2006 - 53.
J. S., Park, K. M., Hsiao, L. L. et al.: Restoration of tubular epithelial cells during repair of the postischemic kidney occurs independently of bone marrow-derived stem cells., 115:Duffield J. S. Park K. M. Hsiao L. L. et al. Restoration of. tubular epithelial. cells during. repair of. the postischemic. kidney occurs. independently of. bone marrow-derived. stem cells. 1743 EOF 55 EOF 2005 - 54.
Kidney tubular epithelium is restored without replacement with bone marrow-derived cells during repair after ischemic injury. 68:Duffield J. S. Bonventre J. V. Kidney tubular. epithelium is. restored without. replacement with. bone marrow-derived. cells during. repair after. ischemic injury. 1956 EOF 1961 EOF 2005 - 55.
36:Liu K. D. Brakeman P. R. Renal repair. recovery S187 EOF S192 EOF 2008 - 56.
Lin, F., Moran, A., Igarashi, P.: Intrarenal cells, not bone marrow-derived cells, are the major source for regeneration in postischemic kidney. , 115:1756 EOF 64 EOF 2005 - 57.
Nayernia, K.: Stem cells derived from testis show promise for treating a wide variety of medical conditions. , 17:895 EOF 7 EOF 2007 - 58.
119:Kanatsu-Shinohara M. Inoue K. Lee J. et al. Generation of. pluripotent stem. cells from. neonatal mouse. testis 1001 EOF 12 EOF 2004 - 59.
, 449:Seandel M. James D. Shmelkov S. V. et al. Generation of. functional multipotent. adult stem. cells from. G. P. R12 germline progenitors. 346 EOF 50 EOF 2007 - 60.
, 456: 344,Conrad S. Renninger M. Hennenlotter J. et al. Generation of. pluripotent stem. cells from. adult human. testis 2008 - 61.
, 37:Zhang Y. Y. Ludwikowski B. Hurst R. et al. Expansion long-term culture. of differentiated. normal rat. urothelial cells. in vitro. 419 EOF 429 EOF 2001 - 62.
: S293,Bharadwaj B. W. S. Rohozinski J. Furth M. Atala A. Zhang Y. Multipotential Differentiation. of Human. Urine-Derived Stem. Cells 2009 - 63.
, 367:Atala A. Bauer S. B. Soker S. et al. Tissue-engineered autologous. bladders for. patients needing. cystoplasty 1241 EOF 1246 EOF 2006 - 64.
, 17:Oberpenning F. Meng J. Yoo J. J. et al. De novo reconstitution. of a. functional mammalian. urinary bladder. by tissue. engineering 149 EOF 55 EOF 1999 - 65.
J. H. et al.: Serum from radiofrequency-injured livers induces differentiation of bone marrow stem cells into hepatocyte-like cells. , 155:Yang Y. Qu B. Huo J. H. et al. Serum from. radiofrequency-injured livers. induces differentiation. of bone. marrow stem. cells into. hepatocyte-like cells. 18 EOF 24 EOF 2009 - 66.
, 13 Suppl 1:Saulnier N. Lattanzi W. Puglisi M. A. et al. Mesenchymal stromal. cells multipotency. plasticity induction. toward the. hepatic lineage. 71 EOF 8 EOF 2009 - 67.
, 189:Mizuguchi T. Hui T. Palm K. et al. Enhanced proliferation. differentiation of. rat hepatocytes. cultured with. bone marrow. stromal cells. 106 EOF 19 EOF 2001 - 68.
, 397:Yaghoobi M. M. Mowla S. J. Differential gene. expression pattern. of neurotrophins. their receptors. during neuronal. differentiation of. rat bone. marrow stromal. cells 149 EOF 54 EOF 2006 - 69.
, 83:Xin H. Li Y. Chen X. et al. Bone marrow. stromal cells. induce B. M. P2 production in. oxygen-glucose-deprived astrocytes. which promotes. an astrocytic. phenotype in. adult subventricular. progenitor cells. 1485 EOF 93 EOF 2006 - 70.
, 47:Shichinohe H. Kuroda S. Yano S. et al. Improved expression. of gamma-aminobutyric. acid receptor. in mice. with cerebral. infarct transplanted bone. marrow stromal. cells an. autoradiographic histologic analysis. 486 EOF 91 EOF 2006 - 71.
, 7:Scintu F. Reali C. Pillai R. et al. Differentiation of. human bone. marrow stem. cells into. cells with. a. neural phenotype. diverse effects. of two. specific treatments. B. M. 14 EOF 2006 - 72.
, 31:Tian H. Bharadwaj S. Liu Y. et al. Myogenic differentiation. of human. bone marrow. mesenchymal stem. cells on. a. . D. nano fibrous. scaffold for. bladder tissue. engineering 870 EOF 877 EOF - 73.
, 96:Zhang Y. Lin H. K. Frimberger D. et al. Growth of. bone marrow. stromal cells. on small. intestinal submucosa. an alternative. cell source. for tissue. engineered bladder. B. J. 1120 EOF 1125 EOF 2005 - 74.
, 174:Chung S. Y. Krivorov N. P. Rausei V. et al. Bladder reconstitution. with bone. marrow derived. stem cells. seeded on. small intestinal. submucosa improves. morphological molecular composition. 353 EOF 9 EOF 2005 - 75.
, 166:Kanematsu A. Yamamoto S. Iwai-Kanai E. et al. Induction of. smooth muscle. cell-like phenotype. in marrow-derived. cells among. regenerating urinary. bladder smooth. muscle cells. 565 EOF 73 EOF 2005 - 76.
, 31: 6207,Sharma A. K. Hota P. V. Matoka D. J. et al. Urinary bladder. smooth muscle. regeneration utilizing. bone marrow. derived mesenchymal. stem cell. seeded elastomeric. poly( 1 8 -octanediol-co-citratebased. thin films. 2010 - 77.
J., Sullivan, R. R. et al.: Defined populations of bone marrow derived mesenchymal stem and endothelial progenitor cells for bladder regeneration. , 182:Sharma A. K. Fuller N. J. Sullivan R. R. et al. Defined populations. of bone. marrow derived. mesenchymal stem. endothelial progenitor. cells for. bladder regeneration. 1898 EOF 1905 EOF 2009 - 78.
Stem Cells.,Sharma A. K. Bury M. I. Marks A. J. et al. Non-Human A. Primate Model. for Urinary. Bladder Regeneration. Utilizing Autologous. Sources of. Bone Marrow. Derived Mesenchymal. Stem Cells. 2010 - 79.
, 25:Strasser H. Marksteiner R. Margreiter E. et al. Transurethral ultrasonography-guided. injection of. adult autologous. stem cells. versus transurethral. endoscopic injection. of collagen. in treatment. of urinary. incontinence 385 EOF 92 EOF 2007 - 80.
, 61:Smaldone M. C. Chen M. L. Chancellor M. B. Stem cell. therapy for. urethral sphincter. regeneration 27 EOF 40 EOF 2009 - 81.
, 64:Peyromaure M. Sebe P. Praud C. et al. Fate of. implanted syngenic. muscle precursor. cells in. striated urethral. sphincter of. female rats. perspectives for. treatment of. urinary incontinence. 1037 EOF 41 EOF 2004 - 82.
, 101:Nolazco G. Kovanecz I. Vernet D. et al. Effect of. muscle-derived stem. cells on. the restoration. of corpora. cavernosa smooth. muscle erectile function. in the. aged rat. B. J. 1156 EOF 1164 EOF 2008 - 83.
,Lu S. H. Yang A. H. Wei C. F. et al. Multi-potent differentiation. of human. purified muscle-derived. cells potential. for tissue. regeneration B. J. 2009 - 84.
,Lu S. H. Yang A. H. Chen K. K. et al. Purification of. human muscle-derived. cells using. an immunoselective. method for. potential use. in urological. regeneration B. J. 2009 - 85.
, 74:Lu S. H. Wei C. F. Yang A. H. et al. Isolation characterization of. human muscle-derived. cells 440 EOF 445 EOF 2009 - 86.
, 61:Lu S. H. Cannon T. W. Chermanski C. et al. Muscle-derived stem. cells seeded. into acellular. scaffolds develop. calcium-dependent contractile. activity that. is modulated. by nicotinic. receptors 1285 EOF 91 EOF 2003 - 87.
, 85:Hoshi A. Tamaki T. Tono K. et al. Reconstruction of. radical prostatectomy-induced. urethral damage. using skeletal. muscle-derived multipotent. stem cells. 1617 EOF 1624 EOF 2008 - 88.
, 62:Cannon T. W. Lee J. Y. Somogyi G. et al. Improved sphincter. contractility after. allogenic muscle-derived. progenitor cell. injection into. the denervated. rat urethra. 958 EOF 63 EOF 2003 - 89.
, 103:Rodriguez L. V. Alfonso Z. Zhang R. et al. Clonogenic multipotent. stem cells. in human. adipose tissue. differentiate into. functional smooth. muscle cells. 12167 EOF 12172 EOF 2006 - 90.
Montzka, K., Heidenreich, A.: Application of mesenchymal stromal cells in urological diseases. ,2009 - 91.
, 30:Jack G. S. Zhang R. Lee M. et al. Urinary bladder. smooth muscle. engineered from. adipose stem. cells three a. dimensional synthetic. composite 3259 EOF 3270 EOF 2009 - 92.
Jack, G. S., Almeida, F. G., Zhang, R. et al.: Processed lipoaspirate cells for tissue engineering of the lower urinary tract: implications for the treatment of stress urinary incontinence and bladder reconstruction., 174: 2041, 2005 - 93.
, 182:Sakuma T. Matsumoto T. Kano K. et al. Mature adipocyte. derived dedifferentiated. fat cells. can differentiate. into smooth. muscle-like cells. contribute to. bladder tissue. regeneration 355 EOF 365 EOF 2009 - 94.
,Smaldone M. C. Chen M. L. Chancellor M. B. Stem cell. therapy for. urethral sphincter. regeneration 2008 - 95.
,Liu J. Huang J. Lin T. et al. Cell-to-cell contact. induces human. adipose tissue-derived. stromal cells. to differentiate. into urothelium-like. cells in. vitro 2009 - 96.
,Lin G. Wang G. Banie L. et al. Treatment of. stress urinary. incontinence with. adipose tissue-derived. stem cells. 2009 - 97.
, 6 Suppl 3:Lin G. Banie L. Ning H. et al. Potential of. adipose-derived stem. cells for. treatment of. erectile dysfunction. 320 EOF 327 EOF 2009 - 98.
,Cavarretta I. T. Altanerova V. Matuskova M. et al. Adipose Tissue-derived. Mesenchymal Stem. Cells Expressing. Prodrug-converting Enzyme. Inhibit Human. Prostate Tumor. Growth 2009 - 99.
, 6:Lin T. Ambasudhan R. Yuan X. et al. chemical A. platform for. improved induction. of human. i. P. S. Cs 805 EOF 808 EOF 2009 - 100.
, 25:De Coppi P. Bartsch G. Jr Siddiqui M. M. et al. Isolation of. amniotic stem. cell lines. with potential. for therapy. 100 EOF 6 EOF 2007 - 101.
Perin L. Sedrakyan S. Da Sacco. S. et al. Characterization of. human amniotic. fluid stem. cells their pluripotential. capability 86 EOF 101 EOF 2008 - 102.
, 63:Perin L. Giuliani S. Sedrakyan S. et al. Stem cell. regenerative science. applications in. the development. of bioengineering. of renal. tissue 467 EOF 471 EOF 2008 - 103.
,Perin L. Giuliani S. Sedrakyan S. et al. Stem Cell. Regenerative Science. Applications in. the Development. of Bioengineering. of Renal. Tissue 2008 - 104.
, 145: 727,Hayashi K. Takahashi M. Kimura K. et al. Changes in. the balance. of phosphoinositide. 3 -kinase/proteinkinase. B. . Akt the mitogen-activated. protein kinases. . E. R. K/p determine M. A. P. K. phenotype a. of visceral. vascular smooth. muscle cells. 1999 - 105.
, 23:Hirst S. J. Twort C. H. Lee T. H. Differential effects. of extracellular. matrix proteins. on human. airway smooth. muscle cell. proliferation phenotype 335 EOF 44 EOF 2000 - 106.
, 11:Hubschmid U. Leong-Morgenthaler P. M. Basset-Dardare A. et al. In vitro. growth of. human urinary. tract smooth. muscle cells. on laminin. collagen type. I-coated membranes. under static. dynamic conditions. 161 EOF 171 EOF 2005 - 107.
J. Q. et al.: Extracellular matrix made by bone marrow cells facilitates expansion of marrow-derived mesenchymal progenitor cells and prevents their differentiation into osteoblasts. , 22:Chen X. D. Dusevich V. Feng J. Q. et al. Extracellular matrix. made by. bone marrow. cells facilitates. expansion of. marrow-derived mesenchymal. progenitor cells. prevents their. differentiation into. osteoblasts 1943 EOF 56 EOF 2007 - 108.
, 16:Tian H. Bharadwaj S. Liu Y. et al. Differentiation of. human bone. marrow mesenchymal. stem cells. into bladder. cells potential. for urological. tissue engineering. 1769 EOF 1779 EOF 2010 - 109.
Biomaterials, 31:Tian H. Bharadwaj S. Liu Y. et al. Myogenic differentiation. of human. bone marrow. mesenchymal stem. cells on. a. . D. nano fibrous. scaffold for. bladder tissue. engineering 870 EOF 877 EOF 2010 - 110.
B, 100:Arrigoni C. Chitto A. Mantero S. et al. Rotating versus. perfusion bioreactor. for the. culture of. engineered vascular. constructs based. on hyaluronic. acid 988 EOF 997 EOF 2008 - 111.
, 67:Gomes M. E. Sikavitsas V. I. Behravesh E. et al. Effect of. flow perfusion. on the. osteogenic differentiation. of bone. marrow stromal. cells cultured. on starch-based. three-dimensional scaffolds. 87 EOF 95 EOF 2003 - 112.
J., Li, Y., Baskin, L. S. et al.: Mesenchymal-epithelial interactions in bladder smooth muscle development: epithelial specificity., 160:Di Sandro M. J. Li Y. Baskin L. S. et al. Mesenchymal-epithelial interactions. in bladder. smooth muscle. development epithelial. specificity 1040 EOF 6%3B EOF 1998 - 113.
, 32: 1238,Kobayashi N. Yasu T. Ueba H. et al. Mechanical stress. promotes the. expression of. smooth muscle-like. properties in. marrow stromal. cells 2004 - 114.
, 106:Akhyari P. Fedak P. W. Weisel R. D. et al. Mechanical stretch. regimen enhances. the formation. of bioengineered. autologous cardiac. muscle grafts. I137 EOF 42 EOF 2002 - 115.
, 232:Paltiel H. J. Diamond D. A. Zurakowski D. et al. Endoscopic treatment. of vesicoureteral. reflux with. autologous chondrocytes. postoperative sonographic. features 390 EOF 7 EOF 2004 - 116.
, 19: 881,Carr L. K. Steele D. Steele S. et al. 1 -yearfollow-up. of autologous. muscle-derived stem. cell injection. pilot study. to treat. stress urinary. incontinence 2008 - 117.
, 67:Capozza N. Patricolo M. Lais A. et al. Endoscopic treatment. of vesico-ureteral. reflux twelve. years’ experience. 228 EOF 231 EOF 2001 - 118.
, 170:Puri P. Chertin B. Velayudham M. et al. Treatment of. vesicoureteral reflux. by endoscopic. injection of. dextranomer/hyaluronic Acid. copolymer preliminary. results 1541 EOF 4%3B EOF 2003 - 119.
, 162:Diamond D. A. Caldamone A. A. Endoscopic correction. of vesicoureteral. reflux in. children using. autologous chondrocytes. preliminary results. 1185 EOF 8 EOF 1999 - 120.
,Zhao W. Zhang C. Jin C. et al. Periurethral Injection. of Autologous. Adipose-Derived Stem. Cells with. Controlled-Release Nerve. Growth Factor. for the. Treatment of. Stress Urinary. Incontinence in. a. Rat Model. 2010 - 121.
, 26:Furuta A. Jankowski R. J. Honda M. et al. State of. the art. of where. we are. at using. stem cells. for stress. urinary incontinence. 966 EOF 71 EOF 2007 - 122.
, 31:De Girolamo L. Sartori M. F. Arrigoni E. et al. Human adipose-derived. stem cells. as future tools. in tissue. regeneration osteogenic. differentiation cell-scaffold interaction. 467 EOF 79 EOF 2008 - 123.
, 8:Furuta A. Jankowski R. J. Pruchnic R. et al. The promise. of stem. cell therapy. to restore. urethral sphincter. function 373 EOF 378 EOF 2007 - 124.
, 81:Stangel-Wojcikiewicz K. Majka M. Basta A. et al. Adult stem. cells therapy. for urine. incontinence in. women 378 EOF 81 EOF 2010 - 125.
Neurourol Urodyn, 29 Suppl 1:Nikolavsky D. Chancellor M. B. Stem cell. therapy for. stress urinary. incontinence S36 EOF S41 EOF 2010 - 126.
J. et al.: Repairing skeletal muscle: regenerative potential of skeletal muscle stem cells. , 120:Tedesco F. S. Dellavalle A. Diaz-Manera J. et al. Repairing skeletal. muscle regenerative. potential of. skeletal muscle. stem cells. 11 EOF 9 EOF 2010 - 127.
, 73:Kim D. K. Jankowski R. J. Pruchnic R. et al. In vitro. in vivo. effect of. lidocaine on. rat muscle-derived. cells for. treatment of. stress urinary. incontinence 437 EOF 441 EOF 2009 - 128.
, 150:Atala A. Kavoussi L. R. Goldstein D. S. et al. Laparoscopic correction. of vesicoureteral. reflux 748 EOF 51 EOF 1993 - 129.
Diamond, D. A., Zurakowski, D., Atala, A. et al.: Is adolescent varicocele a progressive disease process? , 172: 1746,2004 - 130.
Nov;54(5):1208 Note: Bartsch, Georg [removed]]. , 52: 1736,Mitterberger M. Pinggera G. M. Marksteiner R. et al. Functional histological changes. after myoblast. injections in. the porcine. rhabdosphincter.[see comment][erratum. appears in. Eur Urol. 2007 - 131.
, 53:Mitterberger M. Pinggera G. M. Marksteiner R. et al. Adult stem. cell therapy. of female. stress urinary. incontinence 169 EOF 175 EOF 2008 - 132.
179: 226,Mitterberger M. Marksteiner R. Margreiter E. et al. Myoblast fibroblast therapy. for post-prostatectomy. urinary incontinence. 1 -yearfollowup. of . patients 2008 - 133.
, 100: 1081,Mitterberger M. Marksteiner R. Margreiter E. et al. Autologous myoblasts. fibroblasts for. female stress. incontinence a. 1 -yearfollow-up. in 1. patients B. J. 2007 - 134.
, 17:Chancellor M. B. Rivas D. A. Liberman S. N. et al. Cystoscopic autogenous. fat injection. treatment of. vesicoureteral reflux. in spinal. cord injury. 50 EOF 4 EOF 1994 - 135.
181:Arena S. Fazzari C. Implatini A. et al. Dextranomer/hyaluronic Acid. copolymer implant. for vesicoureteral. reflux role. of myofibroblast. differentiation 2695 EOF 2701 EOF 2009 - 136.
, 10:Lin C. S. Xin Z. C. Deng C. H. et al. Recent advances. in andrology-related. stem cell. research 171 EOF 175 EOF 2008